AU2001233847A1 - Interferon-alpha induced genes - Google Patents

Interferon-alpha induced genes

Info

Publication number
AU2001233847A1
AU2001233847A1 AU2001233847A AU3384701A AU2001233847A1 AU 2001233847 A1 AU2001233847 A1 AU 2001233847A1 AU 2001233847 A AU2001233847 A AU 2001233847A AU 3384701 A AU3384701 A AU 3384701A AU 2001233847 A1 AU2001233847 A1 AU 2001233847A1
Authority
AU
Australia
Prior art keywords
interferon
induced genes
alpha induced
alpha
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233847A
Inventor
Michel Dron
Jean Francois Meritet
Michael Gerard Tovey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Pacific Pty Ltd
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002979A external-priority patent/GB0002979D0/en
Priority claimed from GB0002980A external-priority patent/GB0002980D0/en
Priority claimed from GB0002982A external-priority patent/GB0002982D0/en
Priority claimed from GB0002981A external-priority patent/GB0002981D0/en
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of AU2001233847A1 publication Critical patent/AU2001233847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AU2001233847A 2000-02-09 2001-02-09 Interferon-alpha induced genes Abandoned AU2001233847A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0002981 2000-02-09
GB0002979A GB0002979D0 (en) 2000-02-09 2000-02-09 Interferon-alpha induced gene
GB0002980A GB0002980D0 (en) 2000-02-09 2000-02-09 Interferon alpha induced gene
GB0002982A GB0002982D0 (en) 2000-02-09 2000-02-09 Interferon - Alpha induced gene
GB0002982 2000-02-09
GB0002981A GB0002981D0 (en) 2000-02-09 2000-02-09 Interferon alpha inuced gene
GB0002980 2000-02-09
GB0002979 2000-02-09
PCT/GB2001/000541 WO2001058937A2 (en) 2000-02-09 2001-02-09 Interferon-alpha induced genes

Publications (1)

Publication Number Publication Date
AU2001233847A1 true AU2001233847A1 (en) 2001-08-20

Family

ID=27447782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233847A Abandoned AU2001233847A1 (en) 2000-02-09 2001-02-09 Interferon-alpha induced genes

Country Status (6)

Country Link
US (2) US20030186321A1 (en)
EP (1) EP1254224A2 (en)
JP (1) JP2004500821A (en)
AU (1) AU2001233847A1 (en)
CA (1) CA2397254A1 (en)
WO (1) WO2001058937A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030184D0 (en) * 2000-12-11 2001-01-24 Pharma Pacific Pty Ltd Interferon alpha induced gene
WO2005026388A2 (en) * 2003-09-15 2005-03-24 Cenix Bioscience Gmbh The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242329B1 (en) * 1986-04-15 1995-07-19 Ciba-Geigy Ag Monoclonal antibodies against interferon-induced human protein in pure form, and test kits containing these antibodies
US5834235A (en) * 1996-06-21 1998-11-10 Health Research, Incorporated Inferferon-α-induced protein
US7292418B2 (en) * 2004-04-27 2007-11-06 Microsoft Corporation Leakage current interrupter with sustained overvoltage and/or overcurrent protection

Also Published As

Publication number Publication date
US20060099174A1 (en) 2006-05-11
EP1254224A2 (en) 2002-11-06
WO2001058937A3 (en) 2002-04-11
US20030186321A1 (en) 2003-10-02
CA2397254A1 (en) 2001-08-16
JP2004500821A (en) 2004-01-15
WO2001058937A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU2002234755A1 (en) Interferon-alpha induced gene
AU2001278918A1 (en) Novel lipase genes
AU2001242625A1 (en) Gene sequence
AU2001240103A1 (en) Reproduction-specific genes
AU2001264247A1 (en) GASC1 gene
AU6424701A (en) Gasc1 gene
EP1144631A3 (en) Insulin-synthesis genes
AU2001247444A1 (en) Erbeta-mediated gene expression
AUPQ749100A0 (en) New epilespy gene
AU2001285743A1 (en) Adipose-related gene
AU3208801A (en) Interferon-alpha induced genes
AU1873201A (en) Interferon-alpha induced gene
AU2001284265A1 (en) Genetic study
AU2001286120A1 (en) Interferon-alpha induced gene
AU2002222187A1 (en) Interferon-alpha induced gene
AU2001233847A1 (en) Interferon-alpha induced genes
AU2002221623A1 (en) Gene 4
AU2001232088A1 (en) Interferon-alpha induced genes
AU2002310591A1 (en) Interferon-alpha induced gene
AU2001267711A1 (en) Interferon-alpha induced gene
AU2002210985A1 (en) Pca2501 gene
GB0003212D0 (en) Interferon - alpha induced gene
GB0003210D0 (en) Interferon - alpha induced gene
GB0002979D0 (en) Interferon-alpha induced gene
GB0003203D0 (en) Interferon-Alpha induced gene